Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension

Circulation

Volumn 135, Issue 5, 2017, Pages 460-475

  Rhodes, Christopher J ^a   Ghataorhe, Pavandeep ^a   Wharton, John ^a   Rue Albrecht, Kevin C ^a   Hadinnapola, Charaka ^b   Watson, Geoffrey ^a   Bleda, Marta ^b   Haimel, Matthias ^a   Coghlan, Gerry ^c   Corris, Paul A ^d,e   Howard, Luke S ^a   Kiely, David G ^g,h   Peacock, Andrew J ^a   Pepke Zaba, Joanna ⁱ   Toshner, Mark R ^a,j   Wort, S John ^a,k   Gibbs, J Simon R ^f   Lawrie, Allan ^f,h   Gräf, Stefan ^l   Morrell, Nicholas W ^a   Wilkins, Martin R ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^j PAPWORTH HOSPITAL   (United Kingdom)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

hypertension, pulmonary; metabolism; metabolome; metabolomics; pulmonary circulation

Indexed keywords

ACYLCARNITINE; CALCIUM CHANNEL BLOCKING AGENT; FATTY ACID; FUMARIC ACID; GLUTAMIC ACID; MALIC ACID; N1 METHYLINOSINE; N2,N2 DIMETHYLGUANOSINE; NUCLEOSIDE; PHOSPHATIDYLCHOLINE; POLYAMINE; RNA; SPHINGOMYELIN; STEROID; TRANSFER RNA; TRYPTOPHAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOENERGY; CELL PROLIFERATION; CLINICAL OUTCOME; CONTROLLED STUDY; DISEASE CONTROL; ENERGY METABOLISM; FEMALE; HUMAN; LUNG CIRCULATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MORTALITY RISK; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; GENETICS; METABOLISM; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ENERGY METABOLISM; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; METABOLOMICS; MIDDLE AGED; PROGNOSIS; RNA, TRANSFER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85007162504     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.024602     Document Type: Article

References (53)

1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015 46 903 975. doi: 10.1183/13993003.01032-2015.
2. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD, An evaluation of long-Term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012 142 448 456. doi: 10.1378/chest.11-1460.
3. Ryan JJ, Archer SL, Emerging concepts in the molecular basis of pulmonary arterial hypertension, part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation 2015 131 1691 1702. doi: 10.1161/CIRCULATIONAHA.114.006979
4. Maron BA, Leopold JA, Emerging concepts in the molecular basis of pulmonary arterial hypertension, part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation 2015 131 2079 2091. doi: 10.1161/CIRCULATIONAHA.114.006980.
5. Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA 3rd, Soubrier F, Trembath RC, Chung WK, Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009 54 suppl S32 S42. doi: 10.1016/j.jacc.2009.04.015.
6. Ma L, Chung WK, The genetic basis of pulmonary arterial hypertension. Hum Genet 2014 133 471 479. doi: 10.1007/s00439-014-1419-3.
7. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E, Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009 81 6656 6667. doi: 10.1021/ac901536h.
8. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE, Metabolic signatures of exercise in human plasma. Sci Transl Med 2010 2 33ra37. doi: 10.1126/scitranslmed.3001006.
9. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE, Metabolite profiles and the risk of developing diabetes. Nat Med 2011 17 448 453. doi: 10.1038/nm.2307.
10. Shah SH, Kraus WE, Newgard CB, Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012 126 1110 1120. doi: 10.1161/CIRCULATIONAHA.111.060368.
11. Zhao Y, Peng J, Lu C, Hsin M, Mura M, Wu L, Chu L, Zamel R, Machuca T, Waddell T, Liu M, Keshavjee S, Granton J, de Perrot M, Metabolomic heterogeneity of pulmonary arterial hypertension. PLoS One 2014 9 e88727. doi: 10.1371/journal.pone.0088727.
12. Zhao YD, Chu L, Lin K, Granton E, Yin L, Peng J, Hsin M, Wu L, Yu A, Waddell T, Keshavjee S, Granton J, de Perrot M, A biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: metabolomic profiles of arginine, sphingosine-1-phosphate, and heme of human lung. PLoS One 2015 10 e0134958. doi: 10.1371/journal.pone.0134958.
13. Mansoor JK, Schelegle ES, Davis CE, Walby WF, Zhao W, Aksenov AA, Pasamontes A, Figueroa J, Allen R, Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension. PLoS One 2014 9 e95331. doi: 10.1371/journal.pone.0095331.
14. Lewis GD, Ngo D, Hemnes AR, Farrell L, Domos C, Pappagianopoulos PP, Dhakal BP, Souza A, Shi X, Pugh ME, Beloiartsev A, Sinha S, Clish CB, Gerszten RE, Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension. J Am Coll Cardiol 2016 67 174 189. doi: 10.1016/j.jacc.2015.10.072.
15. Box G, Cox D, An analysis of transformations. J Royal Stat Soc 1964 26 211 252
16. Mendes Research Group Web site. http://www.comp-sys-bio.org/software.html
17. de la Fuente A, Bing N, Hoeschele I, Mendes P, Discovery of meaningful associations in genomic data using partial correlation coefficients. Bioinformatics 2004 20 3565 3374
18. Cytoscape. http://www.cytoscape.org/. Accessed March 1, 2016
19. The comprehensive R archive network. http://CRAN.R-project.org/. Accessed December 1, 2015
20. Rhodes CJ, Wharton J, Howard LS, Gibbs JS, Wilkins MR, Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011 97 1054 1060. doi: 10.1136/hrt.2011.224857.
21. Kirchner S, Ignatova Z, Emerging roles of tRNA in adaptive translation, signalling dynamics and disease. Nat Rev Genet 2015 16 98 112. doi: 10.1038/nrg3861.
22. Slotkin W, Nishikura K, Adenosine-To-inosine RNA editing and human disease. Genome Med 2013 5 105. doi: 10.1186/gm508.
23. Torres AG, Batlle E, Ribas de Pouplana L, Role of tRNA modifications in human diseases. Trends Mol Med 2014 20 306 314. doi: 10.1016/j.molmed.2014.01.008.
24. Steinberg S, Cedergren R, A correlation between N2-dimethylguanosine presence and alternate tRNA conformers. RNA 1995 1 886 891
25. Grosjean H, Auxilien S, Constantinesco F, Simon C, Corda Y, Becker HF, Foiret D, Morin A, Jin YX, Fournier M, Fourrey JL, Enzymatic conversion of adenosine to inosine and to N1-methylinosine in transfer RNAs: A review. Biochimie 1996 78 488 501
26. Waalkes TP, Gehrke CW, Zumwalt RW, Chang SY, Lakings DB, Tormey DC, Ahmann DL, Moertel CG, The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer. Cancer 1975 36 390 398
27. Anderson P, Ivanov P, tRNA fragments in human health and disease. FEBS Lett 2014 588 4297 4304. doi: 10.1016/j.febslet.2014.09.001.
28. Mishima E, Inoue C, Saigusa D, Inoue R, Ito K, Suzuki Y, Jinno D, Tsukui Y, Akamatsu Y, Araki M, Araki K, Shimizu R, Shinke H, Suzuki T, Takeuchi Y, Shima H, Akiyama Y, Toyohara T, Suzuki C, Saiki Y, Tominaga T, Miyagi S, Kawagisihi N, Soga T, Ohkubo T, Yamamura K, Imai Y, Masuda S, Sabbisetti V, Ichimura T, Mount DB, Bonventre JV, Ito S, Tomioka Y, Itoh K, Abe T, Conformational change in transfer RNA is an early indicator of acute cellular damage. J Am Soc Nephrol 2014 25 2316 2326. doi: 10.1681/ASN.2013091001.
29. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët DA, Humbert M, Soubrier F, EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014 46 65 69. doi: 10.1038/ng.2844.
30. Sproule DM, Dyme J, Coku J, de Vinck D, Rosenzweig E, Chung WK, De Vivo DC, Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA((Leu)) gene (m.3243A>G). J Inherit Metab Dis 2008 31 suppl 3 497 503. doi: 10.1007/s10545-007-0735-3.
31. Saikia M, Hatzoglou M, The many virtues of tRNA-derived stress-induced RNAs (tiRNAs): discovering novel mechanisms of stress response and effect on human health. J Biol Chem 2015 290 29761 29768. doi: 10.1074/jbc.R115.694661.
32. Seyfarth HJ, Sack U, Gessner C, Wirtz H, Angiogenin, bFGF and VEGF: Angiogenic markers in breath condensate of patients with pulmonary hypertension [in German]. Pneumologie 2015 69 207 211. doi: 10.1055/s-0034-1391775.
33. Shapiro R, Vallee BL, Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin: Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 1989 28 7401 7408
34. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL, Cardiac glutaminolysis: A maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J Mol Med (Berl) 2013 91 1185 1197. doi: 10.1007/s00109-013-1064-7.
35. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H, Shourideh M, Rezaei K, Sartor O, Mohler JL, Vessella RL, Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res 2012 18 5888 5901. doi: 10.1158/1078-0432.CCR-12-1308.
36. Tennant DA, Durán RV, Gottlieb E, Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010 10 267 277. doi: 10.1038/nrc2817.
37. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL, Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 2002 105 244 250. doi: 10.1161/hc0202.101974.
38. Brittain EL, Talati M, Fessel JP, Zhu H, Penner N, Calcutt MW, West JD, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR, Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. Circulation 2016 133 1936 1944
39. DaTorre SD, Creer MH, Pogwizd SM, Corr PB, Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol 1991 23 suppl 1 11 22
40. Schooneman MG, Vaz FM, Houten SM, Soeters MR, Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 2013 62 1 8. doi: 10.2337/db12-0466.
41. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL, Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009 33 318 324. doi: 10.1183/09031936.00000508.
42. Hannun YA, Obeid LM, Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008 9 139 150. doi: 10.1038/nrm2329.
43. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, Petrache I, Schaffer JE, Reisdorph N, Kechris K, Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med 2015 191 275 284. doi: 10.1164/rccm.201410-1771OC.
44. Yano M, Watanabe K, Yamamoto T, Ikeda K, Senokuchi T, Lu M, Kadomatsu T, Tsukano H, Ikawa M, Okabe M, Yamaoka S, Okazaki T, Umehara H, Gotoh T, Song WJ, Node K, Taguchi R, Yamagata K, Oike Y, Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. J Biol Chem 2011 286 3992 4002. doi: 10.1074/jbc.M110.179176.
45. Taniguchi M, Okazaki T, The role of sphingomyelin and sphingomyelin synthases in cell death, proliferation and migration-from cell and animal models to human disorders. Biochim Biophys Acta 2014 1841 692 703. doi: 10.1016/j.bbalip.2013.12.003.
46. Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, Milburn MV, Kastenmüller G, Adamski J, Tuomi T, Lyssenko V, Groop L, Gall WE, Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2013 62 1730 1737. doi: 10.2337/db12-0707.
47. Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF, Ho HY, Yang NI, Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol 2015 65 1509 1520. doi: 10.1016/j.jacc.2015.02.018.
48. Wymann MP, Schneiter R, Lipid signalling in disease. Nat Rev Mol Cell Biol 2008 9 162 176. doi: 10.1038/nrm2335.
49. Ventetuolo CE, Baird GL, Barr RG, Bluemke DA, Fritz JS, Hill NS, Klinger JR, Lima JA, Ouyang P, Palevsky HI, Palmisciano AJ, Krishnan I, Pinder D, Preston IR, Roberts KE, Kawut SM, Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med 2016 193 1168 1175. doi: 10.1164/rccm.201509-1785OC.
50. Alzoubi A, Toba M, Abe K, O'Neill KD, Rocic P, Fagan KA, McMurtry IF, Oka M, Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2013 304 H1708 H1718. doi: 10.1152/ajpheart.00746.2012.
51. Hoet PH, Nemery B, Polyamines in the lung: polyamine uptake and polyamine-linked pathological or toxicological conditions. Am J Physiol Lung Cell Mol Physiol 2000 278 L417 L433
52. Olson JW, Atkinson JE, Hacker AD, Altiere RJ, Gillespie MN, Suppression of polyamine biosynthesis prevents monocrotaline-induced pulmonary edema and arterial medial thickening. Toxicol Appl Pharmacol 1985 81 91 99
53. Zhao YD, Yun HZ, Peng J, Yin L, Chu L, Wu L, Michalek R, Liu M, Keshavjee S, Waddell T, Granton J, de Perrot M, De novo synthesize of bile acids in pulmonary arterial hypertension lung. Metabolomics 2014 10 1169 1175. doi: 10.1007/s11306-014-0653-y.